{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:22:44Z","timestamp":1760955764993},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372375","81473278"],"award-info":[{"award-number":["81372375","81473278"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Project in Suzhou","award":["SYS201524"],"award-info":[{"award-number":["SYS201524"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.molimm.2018.02.017","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T06:08:01Z","timestamp":1520230081000},"page":"78-82","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Polymorphisms in the ICOS\/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients"],"prefix":"10.1016","volume":"96","author":[{"given":"Yong","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanyi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiehong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiguo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2018.02.017_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.molimm.2018.02.017_bib0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/tpj.2010.58","article-title":"Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan","volume":"11","author":"Boni","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.molimm.2018.02.017_bib0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.molimm.2018.02.017_bib0020","doi-asserted-by":"crossref","first-page":"74312","DOI":"10.18632\/oncotarget.19670","article-title":"Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.molimm.2018.02.017_bib0025","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1038\/s41598-017-07491-3","article-title":"A polymorphism in ABCC4 is related to efficacy of 5-FU\/capecitabine-based chemotherapy in colorectal cancer patients","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molimm.2018.02.017_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/35051100","article-title":"ICOS co-stimulatory receptor is essential for T-cell activation and function","volume":"409","author":"Dong","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2018.02.017_bib0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.molimm.2018.02.017_bib0040","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2217\/pgs.12.147","article-title":"miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?","volume":"13","author":"Dreussi","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.molimm.2018.02.017_bib0045","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s13277-015-3980-3","article-title":"MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients","volume":"37","author":"Geng","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0050","first-page":"79","article-title":"Capecitabine in the management of colorectal cancer","volume":"3","author":"Hirsch","year":"2011","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.molimm.2018.02.017_bib0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/16717","article-title":"ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28","volume":"397","author":"Hutloff","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2018.02.017_bib0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0065","first-page":"5391","article-title":"Individual and combined effects of CTLA4-CD28 variants and oxidant-Antioxidant status on the development of colorectal cancer","volume":"35","author":"Kucukhuseyin","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.molimm.2018.02.017_bib0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2016.11.007","article-title":"Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer","volume":"599","author":"Lee","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.molimm.2018.02.017_bib0075","first-page":"642","article-title":"Expression of CD27, CD28 and IL-17A in peripheral blood from patients with colorectal carcinoma","volume":"20","author":"Li","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.molimm.2018.02.017_bib0080","doi-asserted-by":"crossref","first-page":"29794","DOI":"10.18632\/oncotarget.7631","article-title":"The effect of chemotherapy on programmed cell death 1\/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response","volume":"7","author":"Luo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molimm.2018.02.017_bib0085","first-page":"208","article-title":"Impact of the immune system and immunotherapy in colorectal cancer","volume":"6","author":"Markman","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/1758834016646734","article-title":"Current targeted therapies in the treatment of advanced colorectal cancer: a review","volume":"8","author":"Moriarity","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0095","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/carcin\/bgs172","article-title":"Polymorphisms in miRNA-binding sites of nucleotide excision repair genes and colorectal cancer risk","volume":"33","author":"Naccarati","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.molimm.2018.02.017_bib0100","doi-asserted-by":"crossref","first-page":"45124","DOI":"10.1038\/srep45124","article-title":"Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients","volume":"7","author":"Nomizo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molimm.2018.02.017_bib0105","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1158\/1078-0432.CCR-13-0314","article-title":"Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: a potential modulation of microRNAs binding","volume":"19","author":"Pardini","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2018.02.017_bib0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/CBM-170357","article-title":"Correlation of PD-1\/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer","volume":"2","author":"Tan","year":"2018","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.molimm.2018.02.017_bib0120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/carcin\/bgr300","article-title":"The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes","volume":"33","author":"Teo","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.molimm.2018.02.017_bib0125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FPC.0b013e328348c6f2","article-title":"PharmGKB summary: fluoropyrimidine pathways","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.molimm.2018.02.017_bib0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.molimm.2018.02.017_bib0135","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00439-013-1275-6","article-title":"A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma","volume":"132","author":"Wang","year":"2013","journal-title":"Hum. Genet."},{"key":"10.1016\/j.molimm.2018.02.017_bib0140","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2016.00304","article-title":"ICOS Co-Stimulation: friend or foe?","volume":"7","author":"Wikenheiser","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cellimm.2014.11.006","article-title":"Five functional polymorphisms of B7\/CD28 co-signaling molecules alter susceptibility to colorectal cancer","volume":"293","author":"Wu","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0150","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1158\/0008-5472.CAN-10-0527","article-title":"An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity","volume":"70","author":"Wynendaele","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.molimm.2018.02.017_bib0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.humpath.2017.08.016","article-title":"Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma","volume":"68","author":"Yeo","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.molimm.2018.02.017_bib0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jcla.21544","article-title":"Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population","volume":"26","author":"Zhan","year":"2012","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.molimm.2018.02.017_bib0165","doi-asserted-by":"crossref","first-page":"e1141857","DOI":"10.1080\/2162402X.2016.1141857","article-title":"The clinical impact of ICOS signal in colorectal cancer patients","volume":"5","author":"Zhang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.molimm.2018.02.017_bib0170","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.bbrc.2017.07.001","article-title":"Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells","volume":"490","author":"Zhang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molimm.2018.02.017_bib0175","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J. Clin. Invest."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589018300476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589018300476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T23:34:38Z","timestamp":1603928078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589018300476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":35,"alternative-id":["S0161589018300476"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2018.02.017","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymorphisms in the ICOS\/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2018.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}